Table 1.

The development of cholinergic drugs in different stages

Compound	Target	Assignee	Patent number	Phases	Ref.
ZT-1	AChE	Debiopharm SA, Switzerland	WO120774A2 (2009)	Phase II	[16]
(-)-Phenserine	AChE	The General Hospital Corporation, USA	WO117727A2 (2010)	Preclinical	[17]
GLN-1062/Memogain	AChE	Galantos Pharma GmbH, Germany	WO127218A1 (2009)	Discovery	[18]
1a	AChE	Universidad Autonoma de Madrid UAM, Spain	WO051535A1 (2011)	Discovery	[19]
Ladostigil	BChE	Teva Pharmaceutical Industries, Ltd, Israel	US0232691A1 (2007)	Phase II	[20]
NGX267	ACM1	Solvay Pharmaceuticals BV, The Netherlands	WO128674A2 (2007)	Phase II	[21]
EVP-6124	ACHA7	EnVivo Pharmaceuticals, Inc., USA	WO169646A1 (2013)	Phase II	[22]
GTS-21	ACHA7	Niconovum USA, Inc., USA	US0274628A1 (2011)	Phase II	[23]

AChE: Acetylcholinesterase; ACHA7: Neuronal ACh receptor subunit α-7; ACM1: Muscarinic ACh receptor M1; BChE: Butyrylcholinesterase.